Blog
Vopratelimab Biosimilar: A Next-Generation ICOS Agonist for Cancer Immunotherapy
Vopratelimab is a monoclonal antibody targeting inducible T-cell costimulator (ICOS), a key receptor involved in T-cell activation and immune regulation. By selectively activating ICOS,
…
4th Dec 2024